Testicular germ cell tumours
Prepared with OnCo (onco.cc/prep/testicular/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
19 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example AFP, hCG, LDH, miR-371a-3p, i/ 12p gain, Rete testis and lymphovascular invasion, Tumour size >4 cm), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (stage i seminoma), which of the standard options do you recommend and why?
- 6.Am I a candidate for Carboplatin, and what side effects should I expect?
- 7.For my situation (stage i non-seminoma), which of the standard options do you recommend and why?
- 8.Am I a candidate for Bleomycin, Etoposide, Cisplatin, and what side effects should I expect?
- 9.For my situation (metastatic, igcccg good risk), which of the standard options do you recommend and why?
- 10.Am I a candidate for Bleomycin, Etoposide, Cisplatin, and what side effects should I expect?
- 11.For my situation (metastatic, intermediate/poor risk), which of the standard options do you recommend and why?
- 12.Am I a candidate for Bleomycin, Etoposide, Cisplatin or related drugs, and what side effects should I expect?
- 13.For my situation (relapsed), which of the standard options do you recommend and why?
- 14.Am I a candidate for Paclitaxel / nab-paclitaxel, Ifosfamide, Cisplatin or related drugs, and what side effects should I expect?
- 15.Are there clinical trials I could join, for example of Autologous stem cell transplant (high-dose therapy), Carboplatin?
- 16.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 17.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 18.I read that “Platinum-refractory disease has no effective therapy; checkpoint inhibitors were inactive”. How does that affect my plan?
- 19.I read that “Late effects of cisplatin (cardiovascular disease, second cancers, hearing loss) in men cured in their 20s”. How does that affect my plan?
The words I may hear
- Late recurrence: Hormone-driven breast cancer can come back 10 or even 20 years after treatment, unlike most cancers, which is why hormone therapy lasts so long.
- Alpha-fetoprotein (AFP): Alpha-fetoprotein is a protein made by the fetal liver that a substantial share of hepatocellular carcinomas switch back on.
- Retroperitoneum: The space at the back of the abdomen, behind the gut's lining, holding the kidneys, adrenals, pancreas, aorta and the para-aortic lymph nodes.
- Adolescent and young adult (AYA) oncology: Cancer in people aged 15-39, about 90,000 US cases a year, with a distinct mix of cancers, slower survival improvement than children or older adults, and specific needs: fertility, education and work, psychosocial support and trial access.
Tests and results to bring
Biomarker results to ask for: AFP, hCG, LDH (S stage; IGCCCG risk), miR-371a-3p (emerging, high sensitivity for viable GCT), i(12p) / 12p gain, Rete testis and lymphovascular invasion (stage I risk), Tumour size >4 cm (seminoma stage I risk).
Scans and tests linked to this cancer: Active surveillance, AFP, hCG and LDH in germ cell tumours (IGCCCG risk groups), Serum tumour markers: proper use and misuse.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Stage I seminoma: Orchiectomy then surveillance (preferred); adjuvant carboplatin AUC 7 ×1 or para-aortic radiotherapy for those declining surveillance. (Carboplatin, Active surveillance)
- Stage I non-seminoma: Surveillance (relapse ~15-50% by LVI status, all salvageable); or BEP ×1 or nerve-sparing RPLND for high-risk. (Bleomycin, Etoposide, Cisplatin, Active surveillance)
- Metastatic, IGCCCG good risk: BEP ×3 or EP ×4; post-chemotherapy RPLND for residual non-seminoma masses >1 cm. (Bleomycin, Etoposide, Cisplatin)
- Metastatic, intermediate/poor risk: BEP ×4 (or VIP if bleomycin contraindicated); early marker-decline assessment to intensify (GETUG-13); brain metastases treated multimodally. (Bleomycin, Etoposide, Cisplatin, Ifosfamide)
- Relapsed: TIP or VeIP conventional-dose salvage, or high-dose carboplatin-etoposide with autologous stem-cell rescue (TI-CE); TIGER phase 3 compares the two; late relapse and teratoma need surgery. (Paclitaxel / nab-paclitaxel, Ifosfamide, Cisplatin, Carboplatin, Etoposide, Autologous stem cell transplant (high-dose therapy))
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.